Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant and aerosol drug delivery technologies for the treatment of respiratory disorders and other diseases based on KL4 surfactant and capillary aerosol-generating technologies. The company's product pipeline includes Surfaxin, a synthetic, peptide-containing surfactant, Surfaxin LS that enhances ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant. It has a license agreement with Philip Morris USA Inc. and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A.